Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Touts Synergy Bioabsorbable Polymer Stent Trial Data

This article was originally published in The Gray Sheet

Executive Summary

Principle investigator on the Evolve II trial is optimistic the stent will dominate the U.S. market in two to three years.

Advertisement

Related Content

Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US
Boston Sci Says It Will Be Careful About Resorbable Scaffold Investment
Abbott Submits PMA For Absorb Bioresorbable Scaffold
EuroPCR In Brief
Heart Failure Leads Cardio Device Regulatory Activity In Near Term
Longer Anti-Platelet Therapy Reduces Thrombosis Risks With Drug-Eluting Stents

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT033509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel